UCLA studies utilizing mice were the basis for human clinical trials in patients with metastatic breast cancer. This led to the breakthrough breast cancer medication Herceptin, the first cancer-fighting drug to successfully target a specific genetic alteration, thereby limiting side effects such as hair loss and nausea that often accompany conventional therapies.